Deramiocel Shows Promise in Addressing Heart Failure in Duchenne Muscular Dystrophy
Capricor Therapeutics completed submission of their biologics license application to the FDA, seeking approval for deramiocel (CAP-1002) for patients with Duchenne muscular dystrophy (DMD) cardiomyopathy. If accepted, it would be the first approved therapy …